Diagnostic value of contrast-enhanced ultrasound versus computed tomography for hepatocellular carcinoma: a retrospective, single-center evaluation of 234 patients

Vincent Schwarze, Constantin Marschner, Wiebke Völckers, Sergio Grosu, Giovanna Negrão de Figueiredo, Johannes Rübenthaler and Dirk-André Clevert

Abstract
Objective: Hepatocellular carcinoma (HCC) is the most common cause of primary liver cancer. A major part of diagnostic HCC work-up is based on imaging findings from sonography, computed tomography (CT), or magnetic resonance imaging (MRI) scans. Contrast-enhanced ultrasound (CEUS) allows for the dynamic assessment of the microperfusion pattern of suspicious liver lesions. This study aimed to evaluate the diagnostic value of CEUS compared with CT scans for assessing HCC.

Methods: We performed a retrospective, single-center study between 2004 and 2018 on 234 patients with suspicious liver lesions who underwent CEUS and CT examinations. All patients underwent native B-mode, color Doppler and CEUS after providing informed consent. Every CEUS examination was performed and interpreted by a single experienced radiologist (European Federation of Societies for Ultrasound in Medicine and Biology level 3).

Results: CEUS was performed on all included patients without occurrence of any adverse effects. CEUS showed a sensitivity of 94%, a specificity of 70%, a positive predictive value of 93% and a negative predictive value of 72% for analyzing HCC compared with CT as the diagnostic gold standard.

Department of Radiology, Ludwig-Maximilians-University Munich – Grosshadern Campus, Munich, Germany

Corresponding author:
Vincent Schwarze, Department of Radiology, Ludwig-Maximilians-University Munich - Grosshadern Campus, Marchioninistrasse 15, 81379 Munich, Germany.
Email: vincent.schwarze@med.uni-muenchen.de

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Conclusions: CEUS has an excellent safety profile and shows a high diagnostic accuracy in assessing HCC compared with corresponding results from CT scans.

Keywords
Hepatocellular carcinoma, liver, contrast-enhanced ultrasound, computed tomography, lesion, microperfusion

Date received: 18 October 2019; accepted: 7 May 2020

Introduction
Hepatocellular carcinoma (HCC) is the most common cause of primary hepatic cancer, the sixth most common neoplasm, and the second most lethal tumor entity.\textsuperscript{1–3} HCC mainly develops in patients with underlying chronic liver diseases, with varying risks depending on the geographical area. The benefit of HCC surveillance in cirrhotic patients is diagnosing HCC at early stages and thus offering potential curative therapeutic options, as shown in multiple clinical trials.\textsuperscript{4,5} Surveillance of patients with chronic liver disease and at relevant risk for development of HCC, especially with cirrhosis, is recommended by leading hepatology societies.\textsuperscript{6,7} The preferred imaging modality for liver cancer surveillance is ultrasonography with a diagnostic sensitivity up to 80% and a specificity of more than 90%.\textsuperscript{8} Semiannual screening is more beneficial than screening at a 12-month interval. Additionally, a 3-month interval does not show increased survival rates or higher detection rates for small HCC lesions (≤3 cm) and there are higher costs.\textsuperscript{9,10} A disadvantage of sonographic surveillance is its operator dependency. Additionally, tumor markers, such as alpha-fetoprotein, have been evaluated for HCC surveillance.\textsuperscript{11–13} The combination of a sonographic examination and detection of alpha-fetoprotein shows increased detection rates for HCC.\textsuperscript{11} However, valid new biomarkers for early detection of HCC need to be established.

Malignant liver lesions show altered vascularization compared with adjacent unaffected liver parenchyma, while the healthy liver is dominantly supplied by portal venous branches. This results in a typical enhancing pattern of hyperenhancement during the early arterial phase and hypoenhancement/wash-out during the venous or delayed phases on computed tomography (CT) and magnet resonance imaging (MRI) scans. Multiple clinical studies have shown a high diagnostic accuracy for diagnosing HCC using the typical vascularization pattern.\textsuperscript{14} The characteristic vascularization pattern can further dynamically be visualized via contrast-enhanced ultrasound (CEUS).\textsuperscript{15–18} The advantage of non-ionizing CEUS is its safety, immediately availability, repeatability, and cost effectiveness.\textsuperscript{19–23} Using the Liver Imaging Reporting and Data System allows for standardized screening, surveillance, diagnosing, and treatment response assessment of HCC by applying CT, MRI, or CEUS.\textsuperscript{24} In indeterminate cases, biopsy and histopathological analysis need to complement the diagnostic work-up.

This study aimed to evaluate the diagnostic performance of CEUS in assessing HCC lesions compared with findings from corresponding CT scans.

Patients and methods
This retrospective, single-center study was approved by the ethics committee of the Medical Faculty, Ludwig-Maximilians-
University. All contributing authors followed the ethical guidelines for publication in the Journal of International Medical Research. All study data were gathered according to the principles expressed in the Declaration of Helsinki/Edinburgh 2002. Oral and written informed consent of all patients was provided before CEUS examinations and their associated risks and potential complications were carefully described.

All CEUS examinations were performed and analyzed by a single skilled radiologist with experience since 2000 (European Federation of Societies for Ultrasound in Medicine and Biology level 3). All included patients underwent native B-mode, color Doppler, and CEUS scans. Up-to-date, high-end ultrasound systems with adequate CEUS protocols were used (LOGIQ L9; GE Healthcare, Chicago, IL, USA; Ultrasound Sequoia, ACUSON Sequoia; Siemens, Mountain View, CA, USA; Philips Ultrasound iU22, EPIQ 7, Philips, Seattle, WA, USA). A low mechanical index was used to avoid early destruction of microbubbles (<0.2). For all CEUS examinations, the second-generation blood pool contrast agent SonoVue® (Bracco, Milan, Italy) was used. 1.2 to 1.5 mL of SonoVue were applied. SonoVue is a purely intravascular contrast agent that does not diffuse into the interstitial space, thus allowing for dynamic assessment of the microcirculation. After the contrast agent was applied, a bolus of 5 to 10 mL of sterile 0.9% sodium chloride solution was provided. Hepatic lesions of interest were analyzed during the early arterial phase (10–45 s), portal venous phase (30–120 s), and late venous phase (120 s to 4–6 minutes) at intermittent imaging to reduce destruction of microbubbles. All patients were scanned for at least 5 minutes to guarantee thorough visualization of the sonomorphological appearance upon intravenous application of SonoVue. No adverse side effects upon administration of SonoVue® were observed.

All CEUS examinations were successfully performed and the image quality was sufficient in every case. The patients’ files and imaging records were collected from the archiving system of our institution.

A total of 385 patients underwent a CEUS examination of the liver between 2004 and 2018. Of these, 234 also underwent a CT scan in our Department and were included in this retrospective, single-center study. CEUS and CT data were retrieved from the Picture Archiving and Communication System of our institution. Rapid, homogenous, and intense early arterial contrast enhancement following late venous wash-out of the hepatic lesions of interest during CEUS or/and CT was required for establishing the diagnosis of HCC. Contrast-enhanced CT scans were performed using established scanning protocols for evaluation of HCC as follows: native, arterial and portal venous phases of the upper abdomen; and a delayed venous phase of the abdomen at axial, coronal, and sagittal reformation. The extracellular contrast agent Ultravist® 300 mg/mL was used for contrast-enhanced CT scans. Different CT scanners used included Siemens SOMATOM Force, Siemens SOMATOM Definition Flash, and Siemens SOMATOM Definition AS (Siemens Healthcare, Erlangen, Bavaria, Germany).

We analyzed diagnostic sensitivity, specificity, the positive predictive value, the negative predictive value, and the kappa coefficient for assessing interrater reliability of CEUS with CT as the gold standard. Analysis was performed using Graph Pad Prism (GraphPad Software Inc., La Jolla, CA, USA).

Results

Between 2004 and 2018, 234 patients underwent a CEUS examination with a predilection in men (164 male vs. 58 female
patients, 74% vs. 26%, respectively). The mean age of the patients at the time of the CEUS examination was 63 years (range: 20–89 years). We further subdivided HCC lesions into four subtypes depending on the lesion size: <1.0 cm (range: 0.6–0.9 cm; mean: 0.7 cm), 1.0 to 3.0 cm (mean: 2.0 cm), 3.1 to 5.0 cm (mean: 4.1 cm), and >5.0 cm (range: 5.5–18.0 cm, mean: 6.7 cm), which comprised 5%, 48%, 24%, and 23% of the included cohort, respectively.

For the entire cohort, CEUS showed a sensitivity of 94%, a specificity of 70%, a positive predictive value of 93%, and a negative predictive value of 72% for assessing HCC compared with corresponding findings from CT scans as the reference imaging modality. The kappa coefficient between CEUS and CT showed a value of 0.704 (p<0.001). For the subgroups of HCC lesions at sizes of <1.0 cm, 1.0 to 3.0 cm, 3.1 to 5.0 cm, and >5.0 cm, CEUS had a sensitivity of 80%, 92%, 98%, 98%, a specificity of 75%, 57%, 40%, and 67%, a positive predictive value of 80%, 84%, 93%, and 98%, and a negative predictive value of 75%, 57%, 67%, and 67%, respectively.

The HCC-specific contrast enhancement pattern of HCC lesions in CEUS and CT is shown in Figures 1 and 2.

**Discussion**

Conventional ultrasonography, comprising native B-mode and color Doppler, still is the imaging modality of first choice for HCC surveillance in patients with chronic liver disease. The major hepatology societies recommend surveillance of high-risk patients semiannually. CEUS allows for effectively differentiating between various hepatic lesions, such as hemangioma, focal

![Figure 1](image-url)

**Figure 1.** Representative sonomorphological features of hepatocellular carcinoma in contrast-enhanced ultrasound. **a.** Native B-mode shows an inhomogeneous hepatic mass in the right liver lobe. **b.** Intralesional hypervascularization is visualized in color Doppler. **c.** Early arterial hyperenhancement of the lesion in contrast-enhanced ultrasound (left) and the corresponding gray-scale mode (right). **d.** Increased contrast enhancement of the lesion in contrast-enhanced ultrasound with contrast-sparing central necrosis (left) in the arterial phase and corresponding gray-scale mode (right). **e.** Isoechogenicity of the lesion compared with adjacent liver tissue in the portal venous phase (contrast-enhanced ultrasound, left side; gray-scale mode, right side). **f.** Wash-out and resulting hypoechochogenicity of the lesion in the delayed venous phase (contrast-enhanced ultrasound, left side, gray-scale mode, right side).
nodular hyperplasia, metastases, HCC, arteriovenous malformation, and echinococcal manifestations at a lower rate of adverse effects compared with more elaborate imaging modalities. However, the limitations of CEUS must be considered over CT and MRI. These limitations include a restricted ability of staging, limited diagnostic accuracy in people with obesity and cirrhotic patients because of a poor sonic window, and a risk of misdiagnosing intrahepatic cholangiocarcinoma as HCC.

This retrospective, single-center study aimed to assess the diagnostic performance of CEUS in evaluating HCC compared with findings from corresponding CT scans as the reference imaging modality. We found that CEUS had a high diagnostic accuracy in assessing HCC. The kappa coefficient between CEUS and CT findings was 0.704, which is considered as a substantial degree of agreement between CEUS and CT findings. These data are in line with previous studies. In a prospective, clinical study, CEUS showed comparable results with corresponding CT findings visualizing hypervascularization of HCC lesions and even showed superior diagnostic performance considering late venous wash-out. Furthermore, a multicenter trial showed that the diagnostic performance of CEUS was equivalent to that of CT scans concerning tumor differentiation and specification.

The limited diagnostic power of elaborate imaging modalities in case of smaller HCC lesions was described in a retrospective study. This retrospective study showed that typical HCC features were less frequently detected by using MRI in HCC lesions of <1.5 cm in diameter. This diagnosis of features might be improved by using CEUS, which allows for visualization with a striking spatial and temporal resolution. Our results are in line with previous studies showing that CEUS has a high diagnostic accuracy for detecting small HCC lesions.

Figure 2. Computed tomographic morphological features of hepatocellular carcinoma. a. Inhomogeneous mainly hypodense mass in the right liver lobe in the native phase. b. Diffuse early arterial hyperenhancement of the mass in the arterial phase. c. Discrete partial wash-out in the portal venous phase. d. Marked wash-out in the delayed venous phase.
In the present study, in 22 indeterminate findings from CEUS versus CT, contrast-enhanced MRI or histopathology was performed to compare findings with these modalities. In 18/22 cases (82%), MRI/histopathology confirmed findings from CEUS examinations, whereas diagnosis as established by CT was validated in only 4/22 cases (18%). In other cases when results from CEUS strongly indicated HCC and CT, or even MRI scans were not able to visualize a suspicious lesion, a histopathological correlation eventually showed HCC. In one of our cases, CEUS suggested intrahepatic cholangiocellular cancer featuring moderate arterial enhancement in the periphery of the lesion and subsequent early venous wash-out. Corresponding findings from a CT scan suggested HCC. Histopathology finally validated suspected intrahepatic cholangiocellular cancer.43,44 False-negative findings were either correlated with results from MRI or histopathological results and comprised vascular pseudolesions, hemangioma, and echinococcosis. In another of our cases, findings from CEUS and CT scans strongly suggested intrahepatic cholangiocellular cancer, which was histopathologically confirmed. However, CEUS is not recommended as a primary imaging modality by the leading hepatology societies.6,7,45,46

Except for the American Association for the Study of Liver Diseases, CEUS is regarded as a secondary imaging option. The availability, repeatability, excellent safety profile, and economic benefit of CEUS are attractive in the context of liver cancer surveillance. Patients with chronic liver disease have concomitant impaired renal function, and therefore, more elaborate CT and MRI scans are not feasible for these patients. In a recent meta-analysis, no definite recommendation for either extracellular contrast-enhanced CT/MRI or gadoxetate-enhanced MRI for HCC diagnosis was made.14 Both modalities show limited accuracy for lesions of <1.0 cm in diameter. Therefore, there is diagnostic potential of CEUS allowing for real-time visualization of smaller hepatic lesions with high temporal resolution. Our results support this notion. CEUS was recently shown to be complementarily used when MRI results remain indeterminate and CEUS allows for detection of HCC.54

Advantages of CEUS include its capability of dynamically analyzing parenchymal and tumor microperfusion at a more...
accurate temporal and spatial resolution than CT and MRI. Notably, safe application of CEUS in pediatric patients has already been described in several clinical trials and eventually led to its approval for pediatric liver imaging by the Food and Drug Administration. Consequently, CEUS is a powerful diagnostic instrument for evaluating HCC lesions and can be used with less hesitation in renal impairment, hyperthyroidism, pregnancy, and in pediatric patients compared with CT scans. The role of CEUS as a first-line diagnostic tool for characterizing HCC and in the context of cancer surveillance still needs to be determined in future clinical trials.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iD
Vincent Schwarze https://orcid.org/0000-0003-3910-7801

References
1. Villanueva A. Hepatocellular carcinoma. N Engl J Med 2019; 380: 1450–1462. DOI: 10.1056/NEJMra1713263.
2. Jemal A, Ward EM, Johnson CJ, et al. Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. J Natl Cancer Inst 2017; 109. DOI: 10.1093/jnci/djx030.
3. Forner A, Reig M and Bruix J. Hepatocellular carcinoma. Lancet 2018; 391: 1301–1314. DOI: 10.1016/S0140-6736 (18)30010-2.
4. Zhang BH, Yang BH and Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417–422. DOI: 10.1007/s00432-004-0552-0.
5. Sherman M. Surveillance for hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2014; 28: 783–793. DOI: 10.1016/j.bpg.2014.08.008.
6. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology 2018; 68: 723–750. DOI: 10.1002/hep.29913.
7. European Association for the Study of the Liver. Electronic address eee and European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69: 182–236. DOI: 10.1016/j.jhep.2018.03.019.
8. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37–47. DOI: 10.1111/j.1365-2036.2009.04014.x.
9. Santi V, Trevisani F, Gramenzi A, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010; 53: 291–297. DOI: 10.1016/j.jhep.2010.03.010.
10. Trinchet JC, Chaffaut C, Bourcier V, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54: 1987–1997. DOI: 10.1002/hep.24545.
11. Zhang B and Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen 1999; 6: 108–110. DOI: 10.1136/jms.6.2.108.
12. Bialecki ES and Di Bisceglie AM. Diagnosis of hepatocellular carcinoma. HPB (Oxford) 2005; 7: 26–34. DOI: 10.1080/1365182041024049.
13. Lee CW, Tsai HI, Lee WC, et al. Normal alpha-fetoprotein hepatocellular carcinoma: are they really normal? J Clin Med 2019; 8: 1736. DOI: 10.3390/jcm8101736.
14. Roberts LR, Sirlin CB, Zaiem F, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. *Hepatology* 2018; 67: 401–421. DOI: 10.1002/hep.29487.

15. Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver–update 2012: a WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. *Ultraschall Med* 2013; 34: 11–29. DOI: 10.1055/s-0032-1325499.

16. Leoni S, Piscaglia F, Granito A, et al. Characterization of primary and recurrent nodules in liver cirrhosis using contrast-enhanced ultrasound: which vascular criteria should be adopted? *Ultraschall Med* 2013; 34: 280–287. DOI: 10.1055/s-0033-1335024.

17. Seitz K, Strobel D, Bernatik T, et al. Contrast-enhanced ultrasound (CEUS) for the characterization of focal liver lesions – prospective comparison in clinical practice: CEUS vs. CT (DEGUM multicenter trial). Parts of this manuscript were presented at the Ultrasound Dreilandertreffen 2008, Davos. *Ultraschall Med* 2009; 30: 383–389. DOI: 10.1055/s-0028-1109673.

18. Muller-Peltzer K, Rubenthaler J, Reiser M, et al. [Contrast-enhanced ultrasound (CEUS) of the liver: critical evaluation of use in clinical routine diagnostics]. *Radiologe* 2017; 57: 348–355. DOI: 10.1007/s00117-017-0225-z.

19. Piscaglia F, Bolondi L, Italian Society for Ultrasound in M, et al. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations. *Ultrasound Med Biol* 2006; 32: 1369–1375. DOI: 10.1016/j.ultrasmedbio.2006.05.031.

20. Schwarze V, Marschner C, Negrão De Figueiredo G, et al. SonoVue® does not appear to cross the placenta as observed during an examination aimed at confirming a diagnosis of liver echinococcosis in a pregnant woman. *Ultraschall Med* 2020; 41: 146–147. DOI: 10.1055/a-0837-0791.

21. Rubenthaler J, Negrão De Figueiredo G, Mueller-Peltzer K, et al. Evaluation of renal lesions using contrast-enhanced ultrasound (CEUS); a 10-year retrospective European single-centre analysis. *Eur Radiol* 2018; 28: 4542–4549. DOI: 10.1007/s00330-018-5504-1.

22. Negrão De Figueiredo G, Mueller-Peltzer K, Zengel P, et al. Diagnostic performance of contrast-enhanced ultrasound (CEUS) for the evaluation of gallbladder diseases. *Clin Hemorheol Microcirc* 2018; 69: 83–91. DOI: 10.3233/CH-189116.

23. Apfelbeck M, Clevert DA, Ricke J, et al. Contrast enhanced ultrasound (CEUS) with MRI image fusion for monitoring focal therapy of prostate cancer with high intensity focused ultrasound (HIFU)1. *Clin Hemorheol Microcirc* 2018; 69: 93–100. DOI: 10.3233/CH-189123.

24. Chernyak V, Fowler KJ, Kamaya A, et al. Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. *Radiology* 2018; 289: 816–830. DOI: 10.1148/radiol.2018181494.

25. Schwarze V, Marschner C, Negrão De Figueiredo G, et al. Single-center study: evaluating the diagnostic performance and safety of contrast-enhanced ultrasound (CEUS) in pregnant women to assess hepatic lesions. *Ultraschall Med* 2020; 41: 29–35. DOI: 10.1055/a-0973-8517.

26. Tranquart F, Correas JM, Ladam Marcus V, et al. [Real-time contrast-enhanced ultrasound in the evaluation of focal liver lesions: diagnostic efficacy and economical issues from a French multicentric study]. *J Radiol* 2009; 90: 109–122. DOI: 10.1016/j.jradiol.09.70089-7.

27. Strobel D, Seitz K, Blank W, et al. Contrast-enhanced ultrasound for the characterization of focal liver lesions–diagnostic accuracy in clinical practice (DEGUM multicenter trial). *Ultraschall Med* 2008; 29: 499–505. DOI: 10.1055/s-2008-1027806.

28. Strobel D, Seitz K, Blank W, et al. Tumor-specific vascularization pattern of liver metastasis, hepatocellular carcinoma, hemangioma and focal nodular hyperplasia in the differential diagnosis of 1,349 liver lesions in contrast-enhanced ultrasound (CEUS). *Ultraschall Med* 2009; 30: 376–382. DOI: 10.1055/s-0028-1109672.
29. Sporea I, Badea R, Martie A, et al. Contrast enhanced ultrasound for the evaluation of focal liver lesions in daily practice. A multicentre study. Med Ultrason 2012; 14: 95–100.
30. Bernatik T, Seitz K, Blank W, et al. Unclear focal liver lesions in contrast-enhanced ultrasonography—lessons to be learned from the DEGUM multicenter study for the characterization of liver tumors. Ultraschall Med 2010; 31: 577–581. DOI: 10.1055/s-0029-1245649.
31. Ooi CC, Low SC, Schneider-Kolsky M, et al. Diagnostic accuracy of contrast-enhanced ultrasound in differentiating benign and malignant focal liver lesions: a retrospective study. J Med Imaging Radiat Oncol 2010; 54: 421–430. DOI: 10.1111/j.1754-9485.2010.02195.x.
32. Kim TH, Kim SY, Tang A, et al. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol 2019; 25: 245–263. DOI: 10.3350/cmh.2018.0090.
33. Vilana R, Forner A, Bianchi L, et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 2010; 51: 2020–2029. DOI: 10.1002/hep.23600.
34. De Sio I, Iadevaia MD, Vitale LM, et al. Optimized contrast-enhanced ultrasonography for characterization of focal liver lesions in cirrhosis: a single-center retrospective study. United European Gastroenterol J 2014; 2: 279–287. DOI: 10.1177/2050640614538964.
35. Ryu SW, Bok GH, Jang JY, et al. Clinically useful diagnostic tool of contrast enhanced ultrasonography for focal liver masses: comparison to computed tomography and magnetic resonance imaging. Gut Liver 2014; 8: 292–297. DOI: 10.5009/gnl.2014.8.3.292.
36. Trillaud H, Bruel JM, Valette PJ, et al. Characterization of focal liver lesions with SonoVue-enhanced sonography: international multicenter-study in comparison to CT and MRI. World J Gastroenterol 2009; 15: 3748–3756. DOI: 10.3748/wjg.15.3748.
37. Bartolotta TV, Taibbi A, Midiri M, et al. Characterisation of focal liver lesions undetermined at grey-scale US: contrast-enhanced US versus 64-row MDCT and MRI with liver-specific contrast agent. Radiol Med 2010; 115: 714–731. DOI: 10.1007/s11547-010-0506-3.
38. Smajerova M, Petrasova H, Little J, et al. Contrast-enhanced ultrasonography in the evaluation of incidental focal liver lesions: a cost-effectiveness analysis. World J Gastroenterol 2016; 22: 8605–8614. DOI: 10.3748/wjg.v22.i38.8605.
39. Moudgil S, Kalra N, Prabhakar N, et al. Comparison of contrast enhanced ultrasound with contrast enhanced computed tomography for the diagnosis of hepatocellular carcinoma. J Clin Exp Hepatol 2017; 7: 222–229. DOI: 10.1016/j.jch.2017.03.003.
40. Choi MH, Choi JI, Lee YJ, et al. MRI of small hepatocellular carcinoma: typical features are less frequent below a size cutoff of 1.5 cm. AJR Am J Roentgenol 2017; 208: 544–551. DOI: 10.2214/AJR.16.16414.
41. Yang D, Li R, Zhang XH, et al. Perfusion characteristics of hepatocellular carcinoma at contrast-enhanced ultrasound: influence of the cellular differentiation, the tumor size and the underlying hepatic condition. Sci Rep 2018; 8: 4713. DOI: 10.1038/s41598-018-23007-z.
42. Hsiao CY, Chen PD, Huang KW. A prospective assessment of the diagnostic value of contrast-enhanced ultrasound, dynamic computed tomography and magnetic resonance imaging for patients with small liver tumors. J Clin Med 2019; 8: 1353. DOI: 10.3390/jcm8091353.
43. Wildner D, Bernatik T, Greis C, et al. CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial. Ultraschall Med 2015; 36: 132–139. DOI: 10.1055/s-0034-1399147.
44. Li R, Yuan MX, Ma KS, et al. Detailed analysis of temporal features on contrast enhanced ultrasound may help differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma in cirrhosis. PLoS One 2014; 9: e98612. DOI: 10.1371/journal.pone.0098612.
45. Korean Liver Cancer A and National Cancer Center GK. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. *Korean J Radiol* 2019; 20: 1042–1113. DOI: 10.3348/kjr.2019.0140.

46. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int* 2017; 11: 317–370. DOI: 10.1007/s12072-017-9799-9.

47. Venook AP, Papandreou C, Furuse J, et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. *Oncologist* 2010; 15: 5–13. DOI: 10.1634/theoncologist.2010-S4-05.

48. Kolly P and Dufour JF. Surveillance for hepatocellular carcinoma in patients with NASH. *Diagnostics (Basel)* 2016; 6: E22. DOI: 10.3390/diagnostics6020022.

49. Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2011; 9: 428–433; quiz e450. DOI: 10.1016/j.cgh.2011.01.023.

50. Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. *Clin Gastroenterol Hepatol* 2015; 13: 594–601.e1. DOI: 10.1016/j.cgh.2014.08.013.

51. Quaia E, Lorusso A, Grisi G, et al. The role of CEUS in the characterization of hepatocellular nodules detected during the US surveillance program–current practices in Europe. *Ultraschall Med* 2012; 33: S48–S56. DOI: 10.1055/s-0032-1312899.

52. Reinhold C, Hammers L, Taylor CR, et al. Characterization of focal hepatic lesions with duplex sonography: findings in 198 patients. *AJR Am J Roentgenol* 1995; 164: 1131–1135. DOI: 10.2214/ajr.164.5.7717219.

53. Tanaka H, Iijima H, Nouso K, et al. Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography. *Hepatol Res* 2012; 42: 376–384. DOI: 10.1111/j.1872-034X.2011.00936.x.

54. Hu J, Bhayana D, Burak KW, et al. Resolution of indeterminate MRI with CEUS in patients at high risk for hepatocellular carcinoma. *Abdom Radiol (NY)* 2020; 45: 123–133. DOI: 10.1007/s00261-019-02181-2.

55. Seitz K and Strobel D. A milestone: approval of CEUS for diagnostic liver imaging in adults and children in the USA. *Ultraschall Med* 2016; 37: 229–232. DOI: 10.1055/s-0042-107411.